Anti-FLT-1 antibodies in treating duchenne muscular dystrophy
AssigneesShire Human Genetic Therapies, Inc., Regents of the University of Minnesota
InventorsSerene Josiah, Thomas M. Luby, Atsushi Asakura, Dennis Keefe, Lawrence Charnas, Mayank Verma
Life of this patent
Estimating the term…
Abstract
The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of an anti-Flt-1 antibody, or antigen binding fragment thereof, such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset.
Claims7
A method of treating Duchenne Muscular Dystrophy (DMD) comprising administering to an individual who is suffering from or susceptible to DMD an effective amount of an anti-Flt-1 monoclonal antibody, or an antigen binding fragment thereof, such that at least one symptom of DMD is reduced in intensity, severity, or frequency, or has delayed onset, and wherein the anti-Flt-1 monoclonal antibody, or antigen binding fragment thereof, inhibits binding of VEGF to Flt-1 receptor.
Dependencies are inferred from the claim text.